ReviewClinical pharmacokinetics2002
Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Review in Clinical pharmacokinetics, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 163 citations in OpenAlex.
- Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.The pharmacogenomics journal · 2011Pooled it
- The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.Dialogues in clinical neuroscience · 2005Guideline
- Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.Clinical pharmacology and therapeutics · 2011Trial
- Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.Acta pharmacologica Sinica · 2009Trial
- Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.Psychopharmacology · 2007Trial
- Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.European journal of clinical pharmacology · 2004Trial
- Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.European journal of clinical pharmacology · 2003Trial
- Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.Frontiers in pharmacology · 2022Review
- CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.Frontiers in psychology · 2021Article
- Clinical applications of CYP genotyping in psychiatry.Journal of neural transmission (Vienna, Austria : 1996) · 2015Review
- Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.European journal of clinical pharmacology · 2014Article
- Towards the clinical implementation of pharmacogenetics in bipolar disorder.BMC medicine · 2014Article
- Applications of CYP450 testing in the clinical setting.Molecular diagnosis & therapy · 2013Review
- Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report.BMC research notes · 2013Article
- Challenges in pharmacogenetics.European journal of clinical pharmacology · 2013Review
- Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.Schizophrenia research and treatment · 2012Article
- Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus.Archives of medical science : AMS · 2011Article
- Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Pharmacogenomics and personalized medicine · 2011Article
- Genetic polymorphisms of CYP2D6 oxidation in patients with inflammatory bowel disease.Digestive diseases and sciences · 2010Article
- Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Clinical pharmacokinetics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many antipsychotics, including perphenazine, zuclopenthixol, thioridazine, haloperidol and risperidone, are metabolised to a significant extent by the polymorphic cytochrome P450 (CYP) 2D6, which shows large interindividual variation in activity. Significant relationships between CYP2D6 genotype and steady-state concentrations have been reported for perphenazine, zuclopenthixol, risperidone and haloperidol when used in monotherapy. Other CYPs, especially CYP1A2 and CYP3A4, also contribute to the interindividual variability in the kinetics of antipsychotics and the occurrence of drug interactions. For many antipsychotics, the role of the different CYPs at therapeutic drug concentrations remains to be clarified. Some studies have suggested that poor metabolisers for CYP2D6 would be more prone to oversedation and possibly parkinsonism during treatment with classical antipsychotics, whereas other, mostly retrospective, studies have been negative or inconclusive. For the newer antipsychotics, such data are lacking. Whether phenotyping or genotyping for CYP2D6 or other CYPs can be used to predict an optimal dose range has not been studied so far. Genotyping or phenotyping can today be recommended as a complement to plasma concentration determination when aberrant metabolic capacity (poor or ultrarapid) of CYP2D6 substrates is suspected. The current rapid developments in molecular genetic methodology and pharmacogenetic knowledge can in the near future be expected to provide new tools for prediction of the activity of the various drug-metabolising enzymes. Further prospective clinical studies in well-defined patient populations and with adequate evaluation of therapeutic and adverse effects are required to establish the potential of pharmacogenetic testing in clinical psychiatry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.